EAACI Congress 2024
BackOAS 15 - Advancing Atopic Dermatitis care: insights and innovations
Saturday 01 Jun, 15:00 PM -
16:30 PM Valencia, Spain
Granada
Oral Abstract Sessions
15:00
Integrated Safety Analysis of Abrocitinib in 3848 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 7000 Patient-Years With Up to 4.5 Years of Exposure
15:12
Development and Validation of a Clinical Risk Score to Predict Pediatric Atopic Dermatitis in Utero
15:24
Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD)
15:36
Treatment of atopic dermatitis patients with dupilumab restores functional responses of circulating skin-homing CD4+ T and B cells
15:48
Investigation of the inflammatory profile in tears of severe atopic dermatitis patients treated with dupilumab. A study of the BIOBADALER consortium
16:00
Amlitelimab (an OX40 ligand antibody) significantly reduces serum IgE and LDH, and epidermal hyperplasia in adults with moderate-to-severe atopic dermatitis
16:12
Atopic Dermatitis in Children: Exploring the Link between Skin/Blood Markers and Pulmonary Function
